Author:
Magdaleno-Tapial J.,Valenzuela-Oñate C.,Esteban Hurtado Á.,Ortiz-Salvador J.M.,Subiabre-Ferrer D.,Ferrer-Guillén B.,Giacaman-von der Weth M.,García-Legaz Martínez M.,Martínez-Domenech Á.,Hernández-Bel P.,Esteve-Martínez A.,Pérez-Pastor G.,Zaragoza-Ninet V.,García-Rabasco A.,Martínez-Aparicio A.,Sánchez-Carazo J.L.,Pérez-Ferriols A.,Alegre-de Miquel V.
Subject
Dermatology,Histology,Pathology and Forensic Medicine
Reference14 articles.
1. Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading;Takama;Acta Derm Venereol.,2018
2. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients;Kawaguchi;J Diabetes Investig.,2018
3. Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: A disproportionality analysis based on the japanese adverse drug event report database;Arai;Diabetes Care.,2018
4. Vildagliptin significantly increases the risk of bullous pemphigoid: A Finnish Nationwide Registry Study;Varpuluoma;J Invest Dermatol.,2018
5. Inhibition of CD26/Dipeptidyl Peptidase IV Enhances CCL11/Eotaxin-Mediated Recruitment of Eosinophils In Vivo;Forssmann;J Immunol.,2008
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献